Patents by Inventor Renaud Buffet

Renaud Buffet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20240425586
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Application
    Filed: June 3, 2024
    Publication date: December 26, 2024
    Inventors: CÉCILE BONNAFOUS, HÉLÈNE SICARD, RENAUD BUFFET, MATHIEU BLERY
  • Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
    Patent number: 12084498
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: September 10, 2024
    Assignee: INNATE PHARMA
    Inventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet
  • Treatment of peripheral T cell lymphoma
    Patent number: 11999784
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: June 4, 2024
    Assignee: INNATE PHARMA
    Inventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet, Mathieu Blery
  • COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20210363248
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 25, 2021
    Inventors: CÉCILE BONNAFOUS, HÉLÈNE SICARD, RENAUD BUFFET
  • Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
    Patent number: 11078275
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: August 3, 2021
    Assignee: INNATE PHARMA
    Inventors: Cecile Bonnafous, Helene Sicard, Renaud Buffet
  • TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20190315857
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 17, 2019
    Inventors: CÉCILE BONNAFOUS, HÉLÈNE SICARD, RENAUD BUFFET, MATHIEU BLERY
  • Treatment of peripheral T cell lymphoma
    Patent number: 10344087
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: July 9, 2019
    Assignee: INNATE PHARMA
    Inventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet, Mathieu Blery
  • COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20190127463
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 2, 2019
    Inventors: CECILE BONNAFOUS, HELENE SICARD, RENAUD BUFFET
  • Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
    Patent number: 10174112
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: January 8, 2019
    Assignee: INNATE PHARMA
    Inventors: Cecile Bonnafous, Helene Sicard, Renaud Buffet
  • Methods for treatment of recurrent hematological malignancies
    Patent number: 9844593
    Abstract: Compositions comprising compounds that neutralize NK cell inhibitory receptors and methods of using such compositions in the treatment of hematological malignancies are provided.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: December 19, 2017
    Assignee: INNATE PHARMA SA
    Inventors: Pascale Andre, Renaud Buffet, Marcel Rozencweig, Jerome Tiollier
  • COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20170298132
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 19, 2017
    Inventors: CECILE BONNAFOUS, HELENE SICARD, RENAUD BUFFET
  • METHODS FOR RESTORING CORTICOSTEROID SENSITIVITY
    Publication number: 20160136272
    Abstract: The present invention relates to use of therapeutic agents that specifically bind and inhibit TLR3 signalling in order to sensitize patients to treatment with corticosteroids, notably for the treatment and prevention of inflammatory and autoimmune disorders.
    Type: Application
    Filed: May 13, 2014
    Publication date: May 19, 2016
    Inventors: RENAUD BUFFET, CARINE PATUREL
  • A COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20160002345
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnostic of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The disclosure also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Application
    Filed: February 20, 2014
    Publication date: January 7, 2016
    Inventors: CÉCILE BONNAFOUS, HÉLÈNE SICARD, RENAUD BUFFET
  • TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20150376274
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnostic of peripheral T cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express at their surface NKp46, and pharmaceutical compositions comprising the same. The disclosure also relates to use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Application
    Filed: February 13, 2014
    Publication date: December 31, 2015
    Inventors: CÉCILE BONNAFOUS, HÉLÉNE SICARD, RENAUD BUFFET, MATHIEU BLERY
  • NK CELL MODULATING TREATMENTS AND METHODS FOR TREATMENT OF HEMATOLOGICAL MALIGNANCIES
    Publication number: 20130251711
    Abstract: Compositions comprising compounds that neutralize NK cell inhibitory receptors and methods of using such compositions in the treatment of hematological malignancies are provided.
    Type: Application
    Filed: November 22, 2011
    Publication date: September 26, 2013
    Applicant: INNATE PHARMA SA
    Inventors: Pascale Andre, Renaud Buffet, Marcel Rozencweig, Jerome Tiollier